
Keywords: ریزلوزومب; asthma; eosinophil; phase 3; reslizumab; ACQ; Asthma Control Questionnaire; ADA; anti-drug antibody; AE; adverse event; FAS; full analysis set; ICS; inhaled corticosteroid; LABA; long-acting β-agonist; LS; least squares; SABA; short-acting β-agonist;